Humana Inc. (HUM) Stock Competitors & Peer Comparison
See (HUM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HUM | $396.37 | +3.26% | 46.7B | 24.55 | $15.86 | +0.91% |
| UNH | $417.23 | -2.49% | 380.9B | 25.67 | $16.34 | +2.14% |
| CVS | $104.41 | +0.07% | 132.2B | 14.65 | $7.07 | +2.57% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.42% |
| ELV | $388.96 | -1.57% | 84.2B | 12.60 | $30.78 | +1.77% |
| CI | $279.18 | -1.28% | 73.7B | 9.02 | $30.90 | +2.19% |
| CNC | $64.24 | -2.27% | 31.9B | 25.61 | $2.52 | N/A |
| MOH | $227.27 | -1.08% | 12B | 33.17 | $6.92 | N/A |
| OSCR | $28.49 | -4.38% | 7.6B | -49.88 | -$0.59 | N/A |
| ALHC | $23.81 | +2.65% | 4.8B | 258.44 | $0.09 | N/A |
Stock Comparison
HUM vs UNH Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, UNH has a market cap of 380.9B. Regarding current trading prices, HUM is priced at $396.37, while UNH trades at $417.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas UNH's P/E ratio is 25.67. In terms of profitability, HUM's ROE is +0.06%, compared to UNH's ROE of +0.12%. Regarding short-term risk, HUM is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check UNH's competition here
HUM vs CVS Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, CVS has a market cap of 132.2B. Regarding current trading prices, HUM is priced at $396.37, while CVS trades at $104.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas CVS's P/E ratio is 14.65. In terms of profitability, HUM's ROE is +0.06%, compared to CVS's ROE of +0.04%. Regarding short-term risk, HUM is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check CVS's competition here
HUM vs ANTM Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, HUM is priced at $396.37, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas ANTM's P/E ratio is 18.99. In terms of profitability, HUM's ROE is +0.06%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, HUM is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.Check ANTM's competition here
HUM vs ELV Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, ELV has a market cap of 84.2B. Regarding current trading prices, HUM is priced at $396.37, while ELV trades at $388.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas ELV's P/E ratio is 12.60. In terms of profitability, HUM's ROE is +0.06%, compared to ELV's ROE of +0.12%. Regarding short-term risk, HUM is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check ELV's competition here
HUM vs CI Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, CI has a market cap of 73.7B. Regarding current trading prices, HUM is priced at $396.37, while CI trades at $279.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas CI's P/E ratio is 9.02. In terms of profitability, HUM's ROE is +0.06%, compared to CI's ROE of +0.15%. Regarding short-term risk, HUM is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check CI's competition here
HUM vs CNC Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, CNC has a market cap of 31.9B. Regarding current trading prices, HUM is priced at $396.37, while CNC trades at $64.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas CNC's P/E ratio is 25.61. In terms of profitability, HUM's ROE is +0.06%, compared to CNC's ROE of -0.29%. Regarding short-term risk, HUM is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check CNC's competition here
HUM vs MOH Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, MOH has a market cap of 12B. Regarding current trading prices, HUM is priced at $396.37, while MOH trades at $227.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas MOH's P/E ratio is 33.17. In terms of profitability, HUM's ROE is +0.06%, compared to MOH's ROE of +0.04%. Regarding short-term risk, HUM is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check MOH's competition here
HUM vs OSCR Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, OSCR has a market cap of 7.6B. Regarding current trading prices, HUM is priced at $396.37, while OSCR trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas OSCR's P/E ratio is -49.88. In terms of profitability, HUM's ROE is +0.06%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, HUM is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.Check OSCR's competition here
HUM vs ALHC Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, ALHC has a market cap of 4.8B. Regarding current trading prices, HUM is priced at $396.37, while ALHC trades at $23.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas ALHC's P/E ratio is 258.44. In terms of profitability, HUM's ROE is +0.06%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, HUM is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.Check ALHC's competition here
HUM vs CLOV Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, CLOV has a market cap of 2.8B. Regarding current trading prices, HUM is priced at $396.37, while CLOV trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas CLOV's P/E ratio is -44.25. In terms of profitability, HUM's ROE is +0.06%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, HUM is more volatile compared to CLOV. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check CLOV's competition here
HUM vs BHG Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, HUM is priced at $396.37, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas BHG's P/E ratio is -0.12. In terms of profitability, HUM's ROE is +0.06%, compared to BHG's ROE of -0.70%. Regarding short-term risk, HUM is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.Check BHG's competition here
HUM vs CABR Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, CABR has a market cap of 18.6M. Regarding current trading prices, HUM is priced at $396.37, while CABR trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas CABR's P/E ratio is -2.17. In terms of profitability, HUM's ROE is +0.06%, compared to CABR's ROE of -3.00%. Regarding short-term risk, HUM is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.Check CABR's competition here
HUM vs BMGL Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, BMGL has a market cap of 10.6M. Regarding current trading prices, HUM is priced at $396.37, while BMGL trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas BMGL's P/E ratio is -1.29. In terms of profitability, HUM's ROE is +0.06%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, HUM is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.Check BMGL's competition here
HUM vs AET Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, AET has a market cap of 0. Regarding current trading prices, HUM is priced at $396.37, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas AET's P/E ratio is 9.57. In terms of profitability, HUM's ROE is +0.06%, compared to AET's ROE of +0.11%. Regarding short-term risk, HUM is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check AET's competition here
HUM vs GTS Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, GTS has a market cap of 0. Regarding current trading prices, HUM is priced at $396.37, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas GTS's P/E ratio is 10.41. In terms of profitability, HUM's ROE is +0.06%, compared to GTS's ROE of +0.07%. Regarding short-term risk, HUM is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check GTS's competition here
HUM vs MGLN Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, HUM is priced at $396.37, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas MGLN's P/E ratio is 8.49. In terms of profitability, HUM's ROE is +0.06%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, HUM is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check MGLN's competition here
HUM vs UAM Comparison July 2026
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 46.7B. In comparison, UAM has a market cap of 0. Regarding current trading prices, HUM is priced at $396.37, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 24.55, whereas UAM's P/E ratio is 1.01. In terms of profitability, HUM's ROE is +0.06%, compared to UAM's ROE of +0.17%. Regarding short-term risk, HUM is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.Check UAM's competition here